News Snapshot:
COVAXX announced today the first healthy adult volunteers were safely dosed in the company’s Phase 1, open-label, dose-escalation study of the UB-612 vaccine candidate for COVID-19 in Taiwan . The study is partly supported by a grant from the Ministry of Health and Welfare in Taiwan of up to 430M (NTD) or approximately $15M (USD). This clinical trial expands the international collaborations of COVAXX after the recently announced agreements with Dasa, the largest diagnostic medicine company in Brazil and Latin America , and with The University of Nebraska Medical Center to conduct large scale human efficacy clinical trials in Brazil...
